ATTAINMENT OF LDL-C TREATMENT TARGET IN FAMILIAL HYPERCHOLESTEROLEMIA PATIENTS: A THEORETICAL MODEL EXPLORING EFFICACY OF CURRENT AND NOVEL LIPID LOWERING THERAPIES

被引：1

作者：

Hartgers, M. L. ^{[1
]}

Besseling, J. ^{[1
]}

Hovingh, G. K. ^{[1
]}

机构：

[1] Acad Med Ctr, Vasc Med, Amsterdam, Netherlands

来源：

ATHEROSCLEROSIS | 2016年 / 252卷

关键词：

D O I：

10.1016/j.atherosclerosis.2016.07.372

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

EAS16-0724

引用

页码：E43 / E44

页数：2

共 50 条

[1] Attainment of Low-Density Lipoprotein Cholesterol Treatment Target in Familial Hypercholesterolemia Patients: A Model Exploring Efficacy of Current and Novel Lipid Lowering Therapies
Hartgers, Merel L.
Besseling, Joost
Hovingh, G. K.
CIRCULATION, 2016, 134
[2] LDL-C THERAPEUTIC TARGET ATTAINMENT IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA TREATED WITH LOMITAPIDE
Underberg, James
Harada-Shiba, Mariko
Hegele, Robert A.
McCullough, Peter A.
DiGioia, Kenneth
Jurecka, Agnieszka
Stefanutti, Claudia
Blom, Dirk
ATHEROSCLEROSIS SUPPLEMENTS, 2018, 32 : 153 - 154
[3] LDL-C LEVEL AND GOAL ATTAINMENT AMONG PATIENTS WHO SWITCH FROM HIGHER-EFFICACY LIPID LOWERING THERAPIES TO SIMVASTATIN
Cao, X.
Tunceli, K.
Ambegaonkar, B.
Mavros, P.
VALUE IN HEALTH, 2013, 16 (03) : A275 - A275
[4] Evinacumab Lowers LDL-C in Patients With Homozygous Familial Hypercholesterolemia Irrespective of Background Lipid-lowering Medication
Raal, Frederick J.
Rosenson, Robert S.
Reeskamp, Laurens F.
Hovingh, G. Kees
Kastelein, John J.
Rubba, Paolo
Ali, Shazia
Banerjee, Poulabi
Chan, Kuo-Chen
Khilla, Nagwa
McGinniss, Jennifer
Pordy, Robert
Zhang, Yi
Gaudet, Daniel
CIRCULATION, 2020, 142
[5] TREATMENT STATUS OF LDL-C LOWERING THERAPY ACCORDING TO GENETIC VARIANT IN FAMILIAL HYPERCHOLESTEROLEMIA: FROM THE KOREAN FAMILIAL HYPERCHOLESTEROLEMIA (KFH) REGISTRY
Kim, Byung Jin
Choi, Hyo In
Park, Sang Min
ATHEROSCLEROSIS, 2024, 395
[6] Efficacy and Safety of Mipomersen in Patients with Familial Hypercholesterolemia and Inadequately Controlled LDL-C Levels
Ballantyne, Christie
Catapano, Alberico L.
Davidson, Michael
Mittleman, Robert
Moriarty, Patrick M.
Santos, Raul D.
Sensinger, Charlotte
de Banerjee, Samarita
Singleton, Walter
Baker, Brenda F.
Soran, Handrean
Tsimikas, Sotorios
Kastelein, John J.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2016, 36
[7] Achieved LDL cholesterol levels in patients with heterozygous familial hypercholesterolemia: A model that explores the efficacy of conventional and novel lipid-lowering therapy
Hartgers, Merel L.
Besseling, Joost
Stroes, Erik S.
Wittekoek, Janneke
Rutten, Joost H. W.
de Graaf, Jacqueline
Visseren, Frank L. J.
Imholz, Ben P. M.
van Lennep, Jeanine E. Roeters
Huijgen, Roeland
Kastelein, John J. P.
Hovingh, G. Kees
JOURNAL OF CLINICAL LIPIDOLOGY, 2018, 12 (04) : 972 - 980
[8] Multimodal lipid-lowering treatment in pediatric patients with homozygous familial hypercholesterolemia—target attainment requires further increase of intensity
Günter Klaus
Christina Taylan
Rainer Büscher
Claus Peter Schmitt
Lars Pape
Jun Oh
Joenna Driemeyer
Matthias Galiano
Jens König
Carsten Schürfeld
Ralf Spitthöver
Juergen R. Schaefer
Lutz T. Weber
Andreas Heibges
Reinhard Klingel
Pediatric Nephrology, 2018, 33 : 1199 - 1208
[9] Multimodal lipid-lowering treatment in pediatric patients with homozygous familial hypercholesterolemia-target attainment requires further increase of intensity
Klaus, Gunter
Taylan, Christina
Buescher, Rainer
Schmitt, Claus Peter
Pape, Lars
Oh, Jun
Driemeyer, Joenna
Galiano, Matthias
Koenig, Jens
Schuerfeld, Carsten
Spitthover, Ralf
Schaefer, Juergen R.
Weber, Lutz T.
Heibges, Andreas
Klingel, Reinhard
PEDIATRIC NEPHROLOGY, 2018, 33 (07) : 1199 - 1208
[10] Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher
Henry N. Ginsberg
Daniel J. Rader
Frederick J. Raal
John R. Guyton
Marie T. Baccara-Dinet
Christelle Lorenzato
Robert Pordy
Erik Stroes
Cardiovascular Drugs and Therapy, 2016, 30 : 473 - 483

← 1 2 3 4 5 →